Physiologic saline solution

DRUG3 trials

Sponsors

Altair Therapeutics, Inc., CSL Behring

Conditions

Antibody-mediated RejectionAsthma

Phase 1

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

CompletedNCT00658749

Altair Therapeutics, Inc.Asthma

Start: 2008-04-30End: 2009-05-31Updated: 2009-06-25

Phase 2

Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

CompletedNCT00941577

Altair Therapeutics, Inc.Asthma

Start: 2009-10-31End: 2010-06-30Updated: 2010-07-23

Phase 3

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

TerminatedNCT03744910

CSL BehringAntibody-mediated Rejection

Start: 2019-10-14End: 2024-04-08Updated: 2025-07-23

Related Papers

Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.

2023-11-0913 citations

Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Trials2022-12-2236 citations

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10

Transplantation Direct2022-11-1011 citations

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.

2022-09-1519 citations

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Trials2022-04-0823 citations

Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.

2022-02-0935 citations

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism

Transplant International2021-06-227 citations

THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION

Transplantation2020-08-28

Antibodies to watch in 2020.

2020-01-01328 citations